Abstract. The purpose of this study was to develop and evaluate the bioadhesivity, in vitro drug release, and permeation of an intravaginal bioadhesive polymeric device (IBPD) loaded with 3′-azido-3′-deoxythymidine (AZT) and polystyrene sulfonate (PSS). Modified polyamide 6,10, poly(lactic-coglycolic acid), polyacrylic acid, polyvinyl alcohol, and ethylcellulose were blended with model drugs AZT and PSS as well as radio-opaque barium sulfate (BaSO4) and then compressed into caplet devices on a tableting press. One set of devices was coated with 2% w/v pentaerythritol polyacrylic acid (APE-PAA) while another remained uncoated. Thermal analysis was performed on the constituent polymers as well the IBPD. The changes in micro-environmental pH within the simulated human vaginal fluid due to the presence of the IBPD were assessed over a period of 30 days. Textural profile analysis indicated that the bioadhesivity of the APE-PAA-coated devices (3.699±0.464 N; 0.0098±0.0004 J) was higher than that of the uncoated devices (1.198±0.150 N; 0.0019±0.0001 J). In addition, BaSO4-facilitated X-ray imaging revealed that the IBPD adhered to pig vaginal tissue over the experimental period of 30 days. Controlled drug release kinetics was obtained over 72 days. During a 24-h permeation study, an increase in drug flux for both AZT (0.84 mg cm −2 h −1 ) and PSS (0.72 mg cm
INTRODUCTION
The vagina remains a relatively unexplored route of drug delivery in humans despite the potential to be used as a noninvasive route of drug administration (1) . In addition, the vaginal route offers numerous advantages as a localized site for drug delivery due to convenient access, prolonged retention of formulations, an extensive region for drug permeation, high vascularization, a relatively low enzymatic activity, the avoidance of gastrointestinal and/or hepatic firstpass metabolism, and the possibility of self-administration of single-dose drug delivery systems that may suffice in releasing drugs over a period of weeks or months and simultaneously provide optimum drug pharmacokinetic profiles (2) (3) (4) . Thus, intravaginal drug delivery has exploitable advantages compared to other routes of administration in the area of bioavailability and controlled drug delivery (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . A contributing factor to the exploitable advantages conferred by the vaginal route of drug administration is the fact that the adult vaginal cavity has an extensive surface area (100-150 cm 2 ) that is adequately accessible for self-administration purposes (17) . Furthermore, the vaginal route provides room for continuous programmed administration of drugs while simultaneously prevents the superfluous peaking of plasma levels that is often seen with the use of oral drug delivery systems administered as discrete discontinuous doses (17, 18) . However, the localization and prolongation of a drug delivery system at a specific target site with the maintenance of direct contact with the vaginal epithelium in order to increase the drug concentration gradient is still a challenge (2) . This may be overcome by the use of bioadhesive drug delivery devices. The adhesion of a delivery system to mucosal membranes may lead to an increase in drug concentration at the site of action. This may allow greater quantities of drug to be available for absorption to affect the desired therapeutic outcome. Thus, successful development of an intravaginal drug delivery system should consider characteristics of the formulation design, the therapeutic agent, and vaginal physiology (3, 12, 19) .
Given the devastating effects of the HIV/AIDS epidemic and enduring challenges in developing an effective HIV vaccine, coupled with the disempowerment of some women that renders them unable to refuse unsafe sexual practices in certain communities (19) , it is evident that there is an urgent need for developing simple, inexpensive, and acceptable approaches for the prevention of HIV/AIDS and STIs in addition to the latex condom. While numerous drugs and drug delivery systems are being developed, there is still a dire need for new and improved localized drug delivery formulations that will be accepted by the majority of women (19, 20) . One approach that has been explored in this study is the development of a bioadhesive caplet-shaped dual microbicidal delivery device for intravaginal insertion prior to or immediately after intercourse for prevention HIV/STIs transmission. The device is formulated from a precisely selected biodegradable and biocompatible polymer blend and is termed an intravaginal bioadhesive polymeric device (IBPD). The device may be suitable for intravaginal drug delivery that provides controlled drug release kinetics. The thermodynamic behavior of polymers is known to have a significant impact on the physicomechanical properties and therefore their final performance (21, 22) . Therefore, accurate thermal analysis of polymer blends employing temperature-modulated differential scanning calorimetry (TMDSC) is critical for formulation design (23) . TMDSC provides a clearer interpretation of thermal transitions on analyzed samples due to the improved sensitivity and resolution, coupled with the ability to separate reversible glass transitions that have diminutive transitions in heat capacity from overlapping non-reversible relaxation endotherms. TMDSC is also used to reveal thermal transitions at sub-zero temperatures that cannot be detected by conventional DSC due to poor equilibrium of the heat flow baseline below 0°C (24) .
The permeation of most of the drugs across biological tissues has been investigated and presumed to occur through two mechanisms, namely the paracellular (between adjacent epithelial cells) and transcellular (across epithelial cells) routes by means of either passive diffusion, carrier-mediated transport, or endocytosis (25) (26) (27) . Generally, drug diffusion rates correlate with partition coefficients and are inversely proportional to the molecular mass of the drug (3) . For the successful development of an intravaginal drug delivery system, the greatest challenge lies in designing a system that is retainable and can provide a high drug concentration in the vagina over a prolonged period of time (2) .
Therefore the aim of the present study was to design and develop a novel intravaginal bioadhesive polymeric device to prevent sexual transmission of HIV and other STIs. The model drugs/bioactives selected for loading into the IBPD were AZT and polystyrene sulfonate (PSS). The device would provide controlled drug release over an experimental period of at least 1 month when inserted into the posterior fornix of the vaginal cavity. The anterior and posterior vaginal fornices are anatomical recesses that exist due to the projection of the cervix into the vagina. The posterior fornix is the deeper of the two fornices and is most isolated from external interference as a result of menses, coitus, or the application of other therapeutic modalities that may be inserted. The posterior fornix is also located away from the path of menstrual flow, since it lies behind and above the cervix. Therefore, menstrual cycles and shear stress from promiscuous sexual activity will not affect the ability of the IBPD to maintain its adherence in the posterior fornix of the vagina. Thus, the posterior fornix location was purposely chosen so as to avoid any interference to the formulation during menses and sexual intercourse. Since the device was intended to provide prolonged intravaginal drug delivery and subsequent prophylaxis against HIV and STIs a select group of polymers were chosen. These polymers included combinations of biomaterials that were able to impart their inherent properties to constitute the optimal intravaginal formulation for the intended application. Five polymers were employed namely modified polyamide 6,10 ( m PA 6,10), poly(lactide-coglycolic acid) (PLGA), polyacrylic acid (PAA), polyvinyl alcohol (PVA), and ethylcellulose (EC) for preparing the AZT and PSS-loaded IBPD. It was imperative to employ the selected five polymers since each possessed distinct functions based on their intrinsic properties. Modified polyamide 6,10 has a high modulus, thermoplasticity, matrix resilience, abrasion resistance, and chemical inertness. It was thus employed to control drug release, facilitate permeation of drug, and to intensify the robustness of the IBPD. Poly(lactic co-glycolic acid) was selected due to its hydrophobicity and ability to degrade into two acidic units namely lactic and glycolic acid. The presence of these acidic units will produce an acidic pH environment within the vagina upon degradation and thus maintain the normal vaginal ecology by favoring the growth of Lactobacilli-containing microflora that prevents bacterial vaginosis. Furthermore, due to its hydrophobic nature it may aid in controlling drug release from the IBPD. Ethylcellulose is also a hydrophobic and easily compressible polymer. It was therefore selected for formulation of the IBPD. Polyvinyl alcohol, a hydrophilic, compressible, and mildly bioadhesive polymer was included to foster bioadhesivity in conjunction with polyacrylic acid to induce surface energy interactions that favor spreading onto the vaginal mucus for maximal intravaginal tissue retention of the drug.
PSS played a dual role as a matrix polymer and bioactive (28, 29) . PSS acts as a topical broad spectrum antimicrobial agent that can prevent the adherence of the Herpes Simplex Virus at low concentrations and inactivates the virus at higher concentrations (28) (29) (30) (31) (32) (33) (34) . PAA was used as both polymer matrix constituent as well as a coating agent for the purpose of achieving extended bioadhesivity within the posterior fornix of the vagina (35, 36 ). An X-ray imaging approach employing radiopaque barium sulfate (BaSO 4 ) was developed for detecting and determining the sequential biodegradation pattern of the IBPD device in the vagina of the Large White pig as the most suitable animal model for in vivo evaluation of the device. BaSO 4 was employed as a dualfunction formulation excipient in that it imparted matrix stabilization at higher concentrations in addition to its radiopaque properties that facilitated X-ray imaging of the device in the pig vagina. The Large White pig model was selected for this study due to the similarity in the human and pig vagina, particularly the genital tract physiology and histology (37) (38) (39) . In addition, BaSO 4 , which is biocompatible, exhibited desir-able properties of stabilizing the polymeric matrix integrity (40) . The acidic environment in the vagina may be influenced by the changes in pH and ionic concentrations as a result of PLGA degradation into lactic and glycolic acid through cleavage by enzymatic or non-enzymatic hydrolysis (41) (42) (43) . Thus, since PLGA was one of the polymers selected for formulating the IBPD, it was important to determine the changes in micro-environmental pH of the simulated human vaginal fluid (SHVF) when exposed to the degrading constituents of the IBPD. In addition, since chemometric and molecular modeling approaches can precisely explicate various interactive mechanisms of drug release and diffusion dynamics that occur from a drug delivery system, it was employed in this study to elucidate these mechanisms at a molecular level.
MATERIALS AND METHODS

Materials
Modified polyamide 6,10 was synthesized using a previous method developed by Kolawole and co-workers (44) . Poly(lactide-co-glycolide) (Resomer® RG504) was purchased from Boehringer Ingelheim (Ingelheim, Germany). The other commercially available polymers used were allyl pentaerythritol polyacrylic acid (APE-PAA; Carbopol® 974, Noveon Inc., Cleveland, OH, USA), polyvinyl alcohol (Merck-Schuchardt, Hohenbrunn, Germany), and ethylcellulose (Ethocel-10®, Sigma-Aldrich Chemie, Steinheim, Germany). The two model drugs were 3′-azido-3′-deoxythymidine (Evershine Ind., Naejar Malad, Mumbai, India), and polystyrene sulfonate (as a sodium salt; Omega (Pty) Ltd., Montreal, Canada). Methylparaben (Merck (Pty) Ltd., Darmstadt, Germany), shellac (Roeper GmbH, Hamburg, Germany), castor oil (Jayant Oils and Derivatives Ltd., Mumbai, India), and calcium hydroxide (Associated Chemical Enterprises (Pty) Ltd., Southdale, South Africa) were used as formulation stabilizers. Barium sulfate (Merck-Schuchardt, Hohenbrunn, Germany), albumin bovine serum (Sigma-Aldrich Chemie, Steinheim, Germany), acetic acid (Holpro Analytic (Pty) Ltd., Johannesburg, South Africa), and glycerol (Associated Chemical Enterprises (Pty) Ltd., Southdale, South Africa) formed part of the simulated human vaginal or seminal fluids. Pentobarbitone, ketamine (Bayer (Pty) Ltd, Wrenchwerg, Isando, South Africa), midazolam (Roche Products (Pty) Ltd, Isando, Gauteng, South Africa), and isoflurane (Safe Line Pharmaceuticals (Pty) Ltd, Florida, South Africa) were utilized to facilitate the in vivo evaluation of the device. The mobile phase solvents composed of acetonitrile (99.9%) and methanol (99.9%) that were purchased from Romil-SpS™ (Cambridge, UK) including ultra performance liquid chromatography (UPLC) grade water (Milli-Q® A10 System, Millipore®, Molsheim, France). All other reagents used were of analytical grade and were employed as purchased.
Preparation of the Intravaginal Bioadhesive Polymeric Device
An extreme vertices mixture design (EVMD) template was generated employing Minitab® V15 (Minitab® Inc., PA, USA) statistical software to produce various caplet formulations comprising 11 polymer combinations. Each formulation had an equivalent mass of 800 mg. Formulation response optimization was performed using an inherent Doptimal technique by combining mixture components and processing factors to converge to pre-optimal settings prior to achieving a global optimized solution with the desirable polymeric proportions. Two crosslinked forms of polyacrylic acid were tested interchangeably namely allyl sucrose-crosslinked PAA (AS-PAA) and allyl penta erythritol-crosslinked PAA (APE-PAA). Following the results obtained from EVMD template, biodegradable and biocompatible polymers namely m PA 6,10 (150 mg), PLGA (400 mg), APE-PAA (25 mg), PVA (25 mg), and EC (200 mg; which comprised the most optimal formulation) were blended with model drugs AZT (200 mg) and PSS (200 mg) using a cube blender (Erweka® GmbH, Heusenstamm, Germany). Radiopaque BaSO 4 (500 mg) was then added and the powder blend was compressed at a pressure of 25 tons into two sets of caplet-shaped devices on a Manesty D3B 16 station tableting press equipped with D3B oblong tooling of 5×9×22 mm in dimension (Manesty D3B L249LQ, Liverpool, England). In process validation tests were performed to ensure that the IBPD device had desirable quality attributes in terms of matrix hardness, uniformity in mass, and friability.
Pan-Coating of the Intravaginal Bioadhesive Polymeric Device
A dual coating process using the Thai Coater® (Pharmaceutical and Medical Supply Limited Partnership, Yannawa, Bangkok, Thailand) was employed with a protective undercoat comprising shellac and thereafter a mixture of XG and APE-PAA as an overcoat in order to prevent any irritation to the vaginal tissue during device insertion. The addition of APE-PAA was to facilitate bioadhesion of the IBPD to the posterior fornix of the vagina. The process involved firstly undercoating the IBPD with a combination of shellac (4 mg/device), cold-pressed castor oil (3 mg/device), and ethanol (96%). This was followed by an overcoat of XG (2% w/v) and APE-PAA (2% w/v). XG was used for its viscoelastic non-collapsible swellability (45) (46) (47) in order to facilitate bioadhesion of the IBPD in conjunction with APE-PAA that is also biodhesive. The processing conditions utilized for effective coating of the IBPDs were as follows: (1) coating temperature ranged from 50-56°C; (2) relative humidity ranged between 23% and 28%; (3) warming up period was 10 min; (4) the pan was rotated at 2-3 rpm; (5) spray rate was 4 g/min; (6) undercoating duration was 30 min; and (7) the over-coating duration was 60 min. A non-coating period of 30 min was allowed after each coating phase to effect a reduction in pan temperature and avoid sticking or fracture of the undercoat or overcoat seal. The increase in weight after coating the IBPD was determined using an digital balance (Mettler, Model AE 240, Griefensee, Switzerland) while the increase in thickness was determined using a digital vernier caliper (Taizhou Hangyu Tools Gauge and Blades Co., Ltd, Wenqiao, Zhejiang, China) with a sensitivity of 0.01 mm.
In Vitro Drug Release from the Coated and Uncoated Intravaginal Bioadhesive Polymeric Device
Analysis of the Effect of Device Coating on Drug Release
To assess the effect of coating on drug release, analysis was conducted on IBPDs (coated and uncoated) containing AZT as a representative drug model due to its hydrophilicity. An IBPD was immersed in a 100 mL (48,49) SHVF (pH 4.5; 37°C (50); Table I ) using a sealable glass vessel (150 mL) and placed in an orbital shaking incubator (LM-530-2, MRC Laboratory Instruments Ltd., Hahistadrut, Holon, Israel) maintained at 20 rpm and a temperature of 37°C. For the determination of AZT concentration, 3 mL samples were withdrawn at predetermined time intervals over a period of 30 days and subjected to ultra performance liquid chromatography analysis. An equivalent volume of drug-free SHVF was replaced into the release medium to maintain sink conditions. The analysis was conducted in triplicate. A correction factor was appropriately applied in all cases where dilution of samples was required.
Analysis of Drug Release from the Coated Devices Containing AZT and PSS Separately and in Combination
For the analysis of the drug release from the coated devices containing AZT and PSS separately and in combination, the same procedure as described earlier was employed, the only difference being that in this case samples for analysis were withdrawn over a period of 11 weeks.
Chromatographic Conditions for the Analysis of AZT and PSS Concentration
Quantitative analysis was performed using a Waters® Acquity ultra performance liquid chromatographic system (Waters Corp., Milford, MA, USA), equipped with a photodiode array detector and interchangeable columns, namely, a UPLC® BEH phenyl column (1.7 µm; 2.1×50 mm) for AZT separation, and a UPLC® BEH C 18 column (1.7 µm; 2.1× 100 mm) for PSS separation. The binary mobile phases were composed of water/acetonitrile (60:40 v/v) and methanol/ water (50:50 v/v) for AZT and PSS, respectively. All solutions were filtered using a 0.22-µm membrane filter (Millipore Corp., Bedford, Massachusetts, USA) prior to injection onto the UPLC column. For AZT, a gradient method was used at a column temperature of 25°C, injection volume 2 µL, flow rate 0.5 mL/min, and UV detection wavelength of 267 nm. The water/acetonitrile quantities varied from 60/40% at 0.0 min, 5/ 95% (from 1.0-2.6 min), and finally 60/40% (from 3.5-3.6 min). An isocratic assay method was used for PSS separation employing methanol/water (50:50 v/v) as the mobile phase, a flow rate of 0.2 mL/min, a column temperature of 25°C, an injection volume of 1.7 µL and a UV detection wavelength of 244 nm.
Preparation of Calibration Standards
The internal standard employed for both model drugs was methylparaben (MP). Standard solutions of AZT, PSS, and MP (internal standard) were separately prepared by mixing specific quantities in water/acetonitrile (60:40 v/v) for AZT and methanol/water (50:50 v/v) for PSS to yield a concentration of 0.1 mg/mL in each case. The standard solutions employed in preparing the calibration curve of the test drug and internal standard were obtained by further serial dilutions with a final concentration range of 25-10,000 ng/mL. The internal standard solution was prepared at a concentration of 5,000 ng/mL and was added to all samples prepared for UPLC analysis. Calibration curves were developed using blank SHVF (pH 4.5) and computed as a ratio of the area under the curve (AUC) of AZT and PSS chromatographic peaks to that of the internal standard MP against the corresponding standard concentrations of AZT and PSS.
Solid-Phase Extraction Employed for Drug Quantification from SHVF Samples
This was carried out by using single-use Water Oasis® HLB 3 mL (60 mg) extraction cartridge (Waters Corporation, Milford, Massachusetts, USA) adapting a method developed by Notari and co-workers (53) . The solid-phase extraction cartridge was conditioned with 1 mL methanol followed by 1 mL water Milli-Q. For AZT sample preparation, 1 mL of sample was mixed with 1 mL of acetonitrile vortexed for 1 min and centrifuged (Nison Instrument (Shanghai) Limited, Shanghai, China) at 13,000 rpm for 6 min at 24°C. Six hundred fifty microliters of the supernatant was diluted by adding water Milli-Q (1 mL) and loaded in the cartridge. Thereafter, the cartridges were washed with 1 mL of 5% v/v methanol in water Milli-Q. Analytes were eluted by washing cartridges with 550 μL 0.01 M KH 2 PO 4 followed by 2 mL methanol. The eluate was evaporated to dryness in a slow stream of highpurity nitrogen gas (Afrox, Germiston, Gauteng, South Africa). The extracted sample was re-constituted with 100 μL absolute methanol, mixed with 400 μL of MP, and then filtered into the injection vials using 0.22-μm syringe-driven filter units (Millipore Corporation, Bedford, Massachusetts, USA) for UPLC analysis. The same procedure was followed for PSS samples; however, methanol was used as the mobile phase.
Ex Vivo Drug Permeation Studies Through Pig Vaginal Tissue from the Intravaginal Bioadhesive Polymeric Device
The permeation studies to assess the extent of drug permeation across pig vaginal tissue were performed using a Franz diffusion cell apparatus (PermeGear Inc. Bethlehem, PA, USA) equipped with a 12-mL receptor compartment, clamp, and stirrer-bar. Freshly excised pig vaginal tissue obtained from the euthanized Large White pig described above was placed between the donor and receptor compartments of the FDC apparatus. Ten milliliters simulated plasma (pH 7.4; 37°C (51); Table I ) was used in the receptor compartment and continuously agitated. IBPD devices containing AZT and PSS were dissolved in 50 mL SHVF (pH 4.5; 37°C; Table I ) and assessed for the permeation of the drug across the pig vaginal tissue (thickness=1.5±0.06 mm; permeation area=2.0±0.01 cm 2 ) and into the simulated plasma in the receptor compartment. Samples (2 mL) were withdrawn from the receptor compartment, at predetermined intervals over a period of 24 h, and subjected to quantitative drug analysis using UPLC. An equivalent volume of drug-free simulated plasma was replaced into the receptor compartment to maintain sink conditions throughout the permeation study. The analyses were conducted in triplicate. A correction factor was appropriately applied in all cases where dilution of samples was required. The extent of permeation of AZT and PSS across the pig vaginal tissue was determined in terms of drug flux. The flux (mg cm
) of drug across the vaginal tissue was calculated at steady-state per unit area by linear regression analysis of the permeation data using the equation below.
where, J s is the drug flux (mg cm
), Q r (mg) is the quantity of AZT or PSS that diffused through the pig vaginal tissue into the receptor compartment, A (cm −2 ) is the effective cross-sectional area available for drug permeation, and t (h) is the time of drug exposure to the vaginal tissue.
UPLC Analysis of AZT and PSS from Simulated Human Plasma Samples
The chromatographic conditions for the analysis of AZT and PSS concentration in the simulated human plasma fluid (SHPF) were the same as described. Preparation of standard solutions and calibration curves was conducted in the same way as described, the only difference being that calibration curves were developed using blank SHPF (pH 4.5; Table I ) instead of SHVF. The solid-phase extraction procedure employed in the extraction of the drugs from SHPF samples was the same as described.
Postulated Mechanism of Drug Permeation and Dissolution Dynamics from the Intravaginal Bioadhesive Polymeric Device Employing Chemometric and Molecular Modeling
Chemometric and molecular structural modeling was used to deduce the transient mechanisms of diffusion and dissolution, chemical interactions, and inter-polymeric interfacing during the dissolution of the IBPD device and the permeation of AZT and PSS across the vaginal tissue. This approach allowed us to make predictive findings based on the chemical and physical interactions underlying the dissolution of the IBPD and the diffusion of AZT/PSS from the IBPD (contained in the SHVF) and finally the permeation of these drugs to SHPF across the pig vaginal tissue. In addition, semiempirical quantum mechanics were employed to generate molecular interactions and computational energy paradigms of the IBPD components based on inherent interfacial phenomena underlying the mechanisms of dissolution and diffusion as provided by the inter-polymeric blended IBPD. Models and graphics supported on the step-wise molecular IBPD-simulated fluids and IBPD-tissue interactions, polymeric interconversion, dissolution and diffusion as envisioned by the molecular behavior, and stability of the gelled IBPD network were generated on ACD/I-Lab, V5.11 (Add-on) software (Advanced Chemistry Development Inc., Toronto, Canada, 2000).
Influence of the Intravaginal Bioadhesive Polymeric Device on the Micro-environmental pH of the Vagina
The changes in micro-environmental pH within SHVF due to the presence of the IBPD were assessed by incubation of 3 mL SHVF (Table I ; containing the IBPD) in a Multi Purpose Titrator (MPT-2) equipped with a rapid response, liquid-filled glass pH micro-electrode supported on a vertical puller (Malvern Instruments Ltd., Worcestershire, UK). The changes in pH were evaluated from a pH-time profile over 30 days. The electrode calibration standards were adjusted to cover the buffer range from pH 3.5-5.5 with a linear Nernstian response maintained.
Thermal Analysis of the Composite Intravaginal Bioadhesive Polymeric Device
Thermal analysis was performed on the constituent polymers ( m PA 6,10, PLGA, PAA, PVA, and EC) as well as the unhydrated and hydrated physical mixtures of the polymers and the IBPD using TMDSC (Mettler Toledo, DSC1, STAR e System, Schwerzenback, Switzerland) in order to assess the individual thermal behavioral transitions. The thermal events were explicated in terms of the glass transition (T g ) measured as the reversible heat flow (ΔH) due to changes in the magnitude of the C p -complex values (ΔC p ), melting (T m ), and crystallization (T c ) temperature peaks which are consequences of irreversible and reversible ΔH values corresponding to the total heat flow. The temperature calibration was accomplished with the melting transition of indium. The transitions of the individual polymers and their physical mixtures were compared with the transition of the composite IBPD matrix. Samples were weighed (5 mg) on perforated 40 μL aluminum pans, crimped, and then ramped from −35°C to 230°C on TMDSC under a nitrogen atmosphere (Afrox, Germiston, Gauteng, South Africa) in order to diminish oxidation at a rate of 1°C/min. The instrument parameters and settings employed are listed in Table II .
Ex Vivo Bioadhesivity Testing of the Intravaginal Bioadhesive Polymeric Device
Excision of Vaginal Tissue from the Pig Model
A Large White female pig (84 kg) was euthanized with 40 mL of sodium pentobarbitone (200 mg/mL) administered intravenously. The pelvic canal of the pig was opened by dissecting through the symphysis pubis and then exposing the intra-abdominal vaginal tract (the vestibulum). The external vaginal tract was carefully dissected from the surrounding tissues before removing the vaginal tissue. An incision was made through the vaginal canal to expose the inner lining of the tissue, which was then placed in an airtight specimen jar and immediately subjected to bioadhesivity testing.
Textural Profiling Analysis to Determine the Bioadhesivity of the Intravaginal Bioadhesive Polymeric Device
Bioadhesivity of the IBPD was determined using a previous textural profile analysis method developed by Ndesendo and co-workers (36) . Briefly, the freshly excised pig vaginal tissue was secured on the textural probe and the IBPD was fixated onto the heated textural platen after exposure to SHVF (pH 4.5, 37°C; Table I ) for 30 min. Testing was then conducted by measuring the maximum force (N) required to detach the vaginal tissue from the fixated device. This was determined by measuring the peak adhesive force (PAF) or the work of adhesion that was computed as the area under the curve of a force-distance textural profile (AUC FD ). The conditions under which bioadhesivity testing was undertaken constituted a simulated clinical environment using a modified textural analysis experimental technique. A heated platen (37±0.5°C) was used to maintain simulated vaginal conditions prior to fixating the IBPD and during analysis. In addition, all experimentation was performed using simulated human vaginal fluid (pH 4.5; 37°C) as the bioadhesivity test medium.
In Vivo Biodhesivity Testing of the Intravaginal Bioadhesive Polymeric Device
Insertion of the Intravaginal Bioadhesive Polymeric Device into the Vagina of the Pig Model
Three Large White pigs each weighing 35 kg were anesthetized with midazolam (0.3 mg/kg I.M.) and ketamine (11 mg/kg I.M.). Two percent isoflurane in 100% oxygen was administered via a face mask to maintain anesthesia. The IBPD was then deeply inserted into the posterior fornix of the vagina of each pig with the aid of an applicator and a speculum.
X-Ray Imaging of the Pig for Detection of the Intravaginal Bioadhesive Polymeric Device
To detect the presence, position, and retention of the IBPD in the pig vagina after insertion, animals were X-rayed (Siemens AG, Medical Engineering Group, Erlangen, Germany) directly after device insertion and thereafter three times weekly for 2 weeks, then twice weekly for a further 2 weeks to confirm the presence of the IBPD in the vagina and to analyze its swellability and bioerosion dynamics.
RESULTS AND DISCUSSION
Preparation of the Intravaginal Polymeric Device
Optimization of the extreme vertices mixture design template resulted in a formulation comprising m PA 6,10 (150 mg), PLGA (400 mg), APE-PAA (25 mg), PVA (25 mg), and EC (200 mg) (F1, Table III) as the most optimal with desirable polymeric proportions for achieving desirable bioadhesivity and prolonged local delivery of AZT and PSS in the vagina. The optimal formulation obtained from the EVMD template was used for investigating the physicochemical and physicomechanical properties of the IBPD throughout this study.
Coating of the Intravaginal Bioadhesive Polymeric Device
Uniformly coated IBPDs were produced. The final mass for the coated caplets was 1278±0.04 mg while the uncoated caplets weighed 1200±0.01 mg. Thus, the increase in weight was 6.5±0.02% w/w for which the thickness of the coat was 0.520±0.005 mm. 
Analysis of Drug Release from the Coated and Uncoated Optimized Intravaginal Bioadhesive Polymeric Device
A UPLC assay method was used for quantifying the concentration of AZT and PSS released from the IBPD. Chromatograms depicting the retention times for MP (internal standard), AZT, and PSS in SHVF are as shown in Fig. 1a and b .
Assessment of the Effect of Coating on Drug Release from the Intravaginal Bioadhesive Polymeric Device
The shellac/polyacrylic-acid-coated IBPD containing only one of the model hydrophilic drugs, AZT, demonstrated extended drug release when compared to the uncoated devices (28 vs. 20 days; Fig. 2 ). This was due to the shielding effect of the initial shellac undercoat and APE-PAA overcoat applied. Once the APE-PAA coating was hydrated the shellac gradually solubilized in a manner that diffusion channels formed within the coating layer. This facilitated the drug diffusion from the IBPD. Furthermore, shellac (used as an undercoat) shielded the device against the ingress of release medium due to its wax-like properties (54) . This may be attributed to its inherent moisture protecting properties, as well as its ability to act as a plasticizer.
Analysis of Drug Release from the Optimized Coated Intravaginal Bioadhesive Polymeric Device Containing AZT and PSS Separately and in Combination
The substantial matrix integrity imparted by the polymers used to formulate the IBPD resulted in the minimization of the rate of matrix disentanglement and consequently prolonged and controlled the release of AZT and PSS from the IBPD. Controlled drug release representing zero-order was realized consistently over 40 days for AZT and 72 days for PSS (Fig. 3) . These results can be attributed to the hydrophobic nature and high compressibility of EC, PLGA, and PSS, coupled with the superior matrix resilience of m PA 6,10. The electrolytic nature of BaSO 4 may have also contributed to the prolongation and control of drug release. The PSS-loaded IBPD achieved superior drug release behavior with consistent and controlled release over a period of 72 days (Fig. 3d) . For the IBPD loaded with both PSS and AZT, the release of PSS occurred over 56 days compared to 40 days for AZT (Fig. 3b and c) . However, this was still diminutive in comparison to the 72 days achieved from the PSS-only loaded IBPD (Fig. 3d) . Conversely, the period of AZT release from the IBPD was more prolonged than from the AZT-only loaded IBPD device (i.e., 40 vs. 28 days; Fig. 3a  and b) . This was clear that the inclusion of PSS had a significant role in controlling the release of AZT from the IBPD due to the hydrophobicity of PSS and electrostatic and/ or electrolytic properties (as a sodium salt) arising from its polymeric segmental charge density (55) . Studies have shown that charge density of polyelectrolytes such as PSS enhance binding interactions and favors oppositely charged compounds, culminating in the lowering of the rate of desorption and diffusion thereby slowing the drug release rate from the polyelectrolyte compound (55, 56) . The hydrophobicity of PSS results from the presence of strong electrostatic charges and internal linkages (H-and S-bonds) in the residual unsulfonated aromatic moieties of the PSS molecule (57, 58) . In addition, previous studies conducted on polyelectrolytes such as PSS have shown that the higher the osmotic coefficient and radius of gyration, the greater the ability to control the rate of drug release (59) (60) (61) (62) (63) (64) .
Assessment of Drug Permeation Across the Pig Vaginal Tissue
Since the pharmacokinetic and pharmacodynamic performance of the IBPD in the vaginal cavity is critical for ascertaining that a clinical benefit is realized with this approach, adequate local delivery within the vaginal tissue has been assessed under the permeation kinetic studies to ascertain that AZT and PSS are released gradually from the IBPD. The combined release of AZT and PSS may reach therapeutically effective levels for the prophylaxis of HIV and STIs. The flux of AZT and PSS across the pig vaginal tissue over time is shown in Fig. 4 . A relatively constant increase in the rate of flux occurred over the initial 12 h and thereafter saturation was achieved up to 24 h. A mass balance was also 1  150  400  200  25  25  25  2  200  250  300  25  25  25  3  130  260  250  110  50  50  4  200  100  250  150  100  100  5  175  200  250  50  125  125  6  185  275  240  25  75  75  7  175  250  300  25  50  50  8  175  300  275  25  25  25  9  100  50  100  100  225  225  10  200  50  150  200  200  200  11  105  140  175  130  250  250 AS-PAA allyl sucrose-crosslinked PAA, APE-PAA allyl penta erythritol-crosslinked PAA, F# formulation number F# Formulation number m PA 6,10 modified polyamide 6,10 EC ethylcellulose PVA polyvinyl alcohol PLGA poly(lactic-co-glycolic acid) achieved (Fig. 4) . This suggests that the mechanism of passive drug transport across the pig vaginal tissue became saturated. The lower flux of PSS reflects its high degree of hydrophobicity coupled with the presence of strong intermolecular charges in the polymer (65) (66) (67) . This may therefore have contributed to controlling the permeation of the drug across the vaginal tissue. Overall, it can therefore be proposed that the majority of drug was adsorbed onto the surface of the vaginal tissue.
Chemometric and Molecular Modeling of Drug Dissolution and Diffusion from the Intravaginal Bioadhesive Polymeric Device
Postulation of Dissolution Dynamics and Subsequent Effect on Drug Release
Chemometric and computational analysis conducted in our laboratories revealed that polymer-polymer and polymer-drug ratios, as well as the ratio between the coating polymers and components of the dissolution medium contributed substantially to drug dissolution kinetics obtained. Figure 5 depicts a step-wise model of the IBPD undergoing dissolution.
Regarding the physicochemical associations of the polymers, AZT and PSS, all components were homogenous and produced a characteristic even distribution within the IBPD matrix. The hydrophilic and hydrophobic areas of certain polymeric components within the matrix and their association provided the flexible hydration sites. The hydrophilic sites were located within the outer regions of the matrix and the hydrophobic sites were confined to fewer interactive regions at the center of the IBPD matrix. AZT was confined near hydrophilic regions of the matrix while PSS consolidated the inner core as well as areas associated with other hydrophobic polymeric interactions such as PLGA and EC. This segregated hydrophile-hydrophobe clusters within the IBPD matrix was primarily responsible for modulating the diffusion path of drug molecules through the matrix and subsequently controlling drug release. The chemometric and molecular modeling revealed that, remarkably, the rate of transport for the hydrophilic drug AZT compared to the hydrophobic PSS was found to be in a ratio of 3:2 indicating that AZT diffused at a rate that was 1.5 times faster than PSS. This explains the longer controlled release effect obtained when PSS was incorporated into the IBPD device. Through chemometric modeling, it was also ascertained that the difference in molecular mass between AZT and PSS was not solely responsible for this behavior and that the high degree of charge density in PSS, the ionic interactions between the cationic PSS and the polymer constituents as well as the high osmotic coefficient and radius of gyration of PSS, were the primary contributing factors. Changes in vaginal fluid flow rate under normal condition, during sex, and/or menstruation and the presence of any resultant shear do not pose a major factor to interfere with the functionality of the IBPD due to the isolated site of application of the device.
Diffusion Kinetics Depicting the Drug Flux Mechanism During Ex Vivo Studies
The presence of excess SHVF led to complete dissolution of the caplet in the donor compartment of the Franz diffusion cell apparatus during the ex vivo vaginal tissue permeation studies weakening the interactions and physicochemical associations. It was observed that approximately 21% of AZT and 14% of PSS permeated across the pig vaginal tissue in 24 h. The actual transport of the drugs (considering that 16% of both drugs, i.e., 200 mg each in a 1,200 mg IBPD matrix) from the donor compartment to the receptor compartment was 1.662 and 1.180 mg for AZT and PSS, respectively. This indicated that only 3.46% of AZT and 2.46% of PSS permeated through the pig vaginal tissue from the donor compartment to the receptor compartment of the Franz diffusion cells. Thus, the total drug transport across the vaginal tissue was computed as 5.92% with equilibrium achieved after 24 h. A chemometric model depicting the step-wise process of generating diffusion/transport channels perpendicularly to a polymer-strand localized in the IBPD is depicted in Fig. 6 .
With regards to the diffusion kinetics of the IBPD device, the pH of the SHVF had a contributory effect on the transport of drug across the pig vaginal tissue. An osmotic gradient-mediated transport across the vaginal tissue based on the higher concentration of drugs, ions, and other molecular entities in the 2-mL donor compartment of the Franz diffusion cells. The permeation of drug was also inversely proportional to the molecular mass and almost all components, i.e., ions, drugs, polymeric strands, protein, salts, and acids as well as urea from the donor cell permeated though in varying concentrations. The considerable energy paradigms were governed by the solvation of the dissolution medium and osmotic flux. The qualitative status of energy paradigms and energy-time relationships for the IBPD matrix is as shown in Fig. 7a-c . A simple energy status is depicted as a qualitative energy-time relationship for the IBPD matrix as clearly portrayed in Fig. 7a -c.
Micro-environmental pH Variation Analysis Within the SHVF
It was generally observed that the superficial SHVF immediately adjacent to the immersed IBPD exhibited higher pH values than the SHVF immediately surrounding the device. The initial pH, measured as close as possible to the device, upon insertion of the IBPD into the titration system (MPT-2) was 4.5±0.01 (N=3). The pH electrode was inserted using a Narashige micro-manipulator and was submerged towards the IBPD by careful hydraulic micro-movements to avoid creating any unnecessary turbulent hydrodynamic flow. A slight drop in pH was routinely recorded as the electrode passed in proximity to the IBPD with a slightly more acid pH than the entire SHVF (pH 4.48±0.02) around a superficial surface diameter of 5 mm. The pH, measured away from the superficial layer was 4.58±0.03 (N=3). The relatively higher pH at the superficial layer may be have been due to the extruding OH − ions from m PA 6,10, EC, PAA, or PVA. The relatively lower pH observed at the IBPD proximity (microenvironmental pH) could most certainly have been due to the breakdown of PLGA into lactic and glycolic acids. This biphasic response in pH was observed over an experimental period of 30 days. A profile depicting this sequence is shown in Fig. 8 .
Attempts were made to perturb the inherent pH of the SHVF by adding incremental volumes of SHSF (52) (pH 7.0; 37°C) (Table I ) (a significantly greater volume than would be produced on degradation of the PLGA-based IBPD in the SHVF) to simulate the presence of semen during/after sexual intercourse. After the addition of SHSF, the pH recorded within the SHVF was 4.58+0.02 (N=3) and not significantly different from the resting pH of 4.50 (P<0.01). Upon further addition of SHSF into the MPT-2, the inherent pH was reduced to 4.52±0.03 (N=3) indicating that the SHVF was able to maintain its internal pH close to a value of 4.50 in the presence of a more alkaline medium (e.g., seminal fluid).
Overall the results portrayed the potential of the IBPD to control and buffer the pH range of 3.5-5.5 in the SHVF by the virtue of the degradation of PLGA to lactic and glycolic acids. This pH range is the same as that produced by Lactobacilli species (68) which plays a vital role in keeping the vagina healthy. It also covers the average pH range of a normal healthy human vagina which is 4-5 (69-71) indicating the suitability of the IBPD for the intended purpose.
Thermal Analysis of the Composite Intravaginal Bioadhesive Polymeric Device
The thermal stability of the constituent polymers as well as the composite unhydrated IBPD was investigated by TMDSC at a temperature range from −35°C to 230°C. The polymers displayed multi-transitional thermal behaviors with multiple glass transition temperature (T g ), melting temper- Fig. 5 . Molecular model mechanistically depicting the IBPD dissolution process with lesser H-bond formation due to the excessive of SHVF providing more freedom for polymeric strands to disentangle Fig. 6 . Chemometric model depicting the development of a diffusion channel with a) a single polymer strand P, situated perpendicularly to a forming pore C, b) a group of strands also denoted collectively as P giving rise to the channel C which is formed perpendicular to the polymer strand backbone with F = the direction of flow from the starting point S to form a networked 3D channel and c) a polymeric strand with the generated diffusion channel ature (T m ), and crystallization temperature (T c ) values (Table IV) that were attributed to the existence of reversing and non-reversing endothermic signals arising from the transient melting of molecules within each polymer.
Characterization of the Native Unhydrated Polymer Constituents of the IBPD
Ethylcellulose and Modified Polyamide 6,10
EC was characterized by a T g at 100°C and an exothermic T c at 130°C (Table IV ). The T m of EC occurred at 170°C which was relatively high compared to the other polymers. This revealed the superior thermodynamic stability of the polysaccharide subunits of EC. The m PA 6,10 had a distinct T g at 163°C and two endothermic T m values at 65°C and 140°C. In addition, two exothermic T c peaks of m PA 6,10 were observed at 120°C and 200°C that followed the melting phases (Table IV) . This suggested partial decomposition of m PA 6,10 that may be related to mass loss and the fact that the aliphatic polyamides inherently have a high heat of fusion and low entropy of fusion dependent on the collective dissociation energy of intramolecular H-bonds before any macroscopic dimensional changes can be realized (72, 73) .
Poly(lactic-co-glycolic Acid), Polyvinyl Alcohol, and Poly (acrylic Acid)
PLGA was characterized by two T g values (Table IV) . The first T g peak appeared during the initial heating scan in which an enthalpy of relaxation peak superimposed the T g between 45°C and 55°C. The second T g value at 210°C was also noted as PLGA is a quench cooled amorphous material (74) . As heating proceeded, the T g and the temperature at the apex of the overheating peak shifted to higher temperatures (T g =210°C; T m =220°C; Table IV) due to the formation of a percolated network structure resulting from the quench cooling properties of PLGA. Thermograms for PVA revealed two T g values at 22°C and 115°C and two endothermic T m peaks at 30°C and 180°C (Table IV) due to the thermal decomposition of the ordered PVA elements. Thermodynamic analysis of PVA isotherms and crystallite growth rates has shown that crystallization of PVA (163°C; 215°C) is one dimensional (75) . Thus, due to the absence of water or other swelling agents, kinetic hindrances predominated as a Table IV . The broad endothermic peak (130-170°C) resulted from conformational changes in the macromolecules of PAA related to the magnitude of crosslinking interactions between the proton-donating pendent COOH − groups and polar OH − groups of PAA during synthesis (76) . The presence of COOH − groups favored the bioadhesiveness of PAA to the pig vaginal tissue when used as a coating agent for the IBPD device.
Characterization of the Unhydrated IBPD
Thermal analysis of the IBPD revealed a T g at 150°C, two T c peaks at 140°C and 220°C and a T m peak at 220°C (Table IV) . The presence of transient T m peaks in the total TMDSC signals for the IBPD indicated that the polymers were dispersed within the device matrix. In addition, diminutive exothermic events were observed at the corresponding T c ranges for the constituent polymers indicating a high degree of crystallinity within the device matrix structure. The deconvolution of the total TMDSC signals for the IBPD in terms of reversing and non-reversing events reflected the average of the equivalent signals for each polymer. However, for the IBPD the T m appeared to be predominantly reversing due to the concurrent re-crystallization and melting phenomena that offset one another. This indicated that solid-solid phase transitions may have occurred within the IBPD due to polymeric compression, and subsequently contributed to the prolongation and control of drug from the device. Thus, the thermodynamic stability of polymers/polymer blends may affect the drug release process and can therefore be used to predict the drug release behavior based on unequivocally defined thermodynamic events.
Characterization of Unhydrated and Hydrated Physical
Polymer Blends as well as Hydrated IBPD TMDSC analysis was also performed on hydrated and unhydrated physical blends of the constituent polymers of the IBPD as well as the hydrated IBPD in order to determine the effect of compression on the polymer blend. Thermograms obtained on the hydrated and unhydrated physical polymer blends as well as the hydrated and unhydrated IBPD are depicted in Fig. 9 and Table IV. Overall, there was a distinct similarity between thermal events of the hydrated physical polymer blend and the hydrated IBPD (Fig. 9a and c) . Thermograms presented with regions associated with very low temperatures (−10°C and −15°C) for the hydrated samples of the physical polymer blend and the IBPD while dehydration was complete at 200°C (Fig. 9a and c) . However, the thermal behavior for the unhydrated physical polymer blend was markedly different from that of the unhydrated IBPD ( Fig. 9b and d) . This was attributed primarily to the effect of polymer compression on the physical polymer blend to produce the device.
For the hydrated physical polymer blend (Fig. 9a) , the onset of the low-temperature endothermic T m peaks (−15°C and 22°C) was attributed to the high moisture content in the physical polymer blend while the apparent T m peaks (163°C and 200°C) resulted from the loss of residual water as heating Fig. 11 . X-ray images depicting the presence of the coated intravaginal bioadhesive polymeric device at a) day 1, b) day 14, and c) day 30 after insertion into the posterior fornix of the pig vagina proceeded. The T m endotherms were distinctly separated from the total heat flow in the non-reversing signal. Contrary to the hydrated physical polymer blend, the unhydrated polymer blend showed fewer thermal events (Fig. 9b) . A single T g at 170°C and a T m peak at 200°C were observed (Fig. 9b) . Furthermore, the T g and T m peaks that appeared for the hydrated physical polymer blend prior to 170°C, were absent in the unhydrated polymer blend (Fig. 9b) . This may be associated with a baseline transition at ±170°C in the reversing heat flow signal. Overall, the hydrated physical polymer blend presented with lower T m peaks (22°C and 163°C). These observations were consistent with previous results reported by Frushour (77) where, upon hydrating a physical polymer blend, the T m peak was reduced well below the onset temperature.
Ex Vivo Bioadhesivity Analysis of the Intravaginal Bioadhesive Polymeric Device
The devices that were produced were strongly bioadhesive. Textural profile analysis indicated that the uncoated devices had the lowest bioadhesivity (PAF=1.1976±0.150 N; AUC FD =0.0019±0.0001 J) compared with the PAA-coated devices (PAF=3.699±0.0.464 N; AUC FD =0.0098±0.0004 J; Fig. 10a and b) . This indicates the superiority of APE-PAA as a bioadhesive coating as may be attributed to its hydrophilicity, H-bonding capacity, the high molecular mass, and the surface tension properties of the polymer. Polyacrylic controlled the extent of interpenetration between the polymer and the vaginal mucosal/epithelial surface. The high hydrophilicity of APE-PAA enabled the formation of strong bioadhesive bonds due to the high water content within the mucosal layer of the pig vaginal tissue. The presence of OH − and COOH − groups in APE-PAA may have favored the formation of H-bonds between the entangled APE-PAA chains and the pig vaginal tissue that ultimately resulted in bioadhesion. In addition, the desirable surface tension of PAA facilitated spreading over the epithelial surface of the vaginal mucosal layer thereby enhancing bioadhesion.
Retention of the Intravaginal Bioadhesive Polymeric Device Within the Pig Vagina
Analysis of X-ray images (Fig. 11) revealed that the coated devices were maintained in the posterior fornix of the pig vagina for the experimental period up to 30 days. The devices underwent swelling and gradually eroded over time as shown in Fig. 11a, b , and c which is in accordance with the stipulated design in which the formulation is expected to initially swell in order to facilitate bioadhesion and thereafter gradually erode and release the drug over the vaginal tissue for the required clinical preventative effect.
CONCLUSIONS
Robust polymeric devices were produced that confirmed the ability of the polymer blend selected ( m PA 6,10, PLGA, PVA, PAA, and EC) to control the release of the model drugs AZT and PSS over a period of 72 days. The thermodynamic stability of the native polymers and device was substantiated by TMDSC thermograms. Ex vivo bioadhesion and permeation studies revealed that the APE-PAA-coated devices were desirably bioadhesive and a relatively substantial fraction of the drug load was confined within the vaginal tissue. The produced IBPDs showed the potential of maintaining the acidic micro-environmental pH of the SHVF upon degrading which is a desirable feature in the vagina. The chemometric and molecular structural modeling approach qualitatively supported the deduction of the IBPD rate of dissolution and has shown that the drug release rate was dependent on the stoichiometric parameters between the polymers, drugs, and the SHVF. Furthermore, it was mechanistically deduced that the permeation of drug across the pig vaginal tissue during ex vivo studies was based on an osmotic gradient and depended on the degree of ionization as well as the size and molecular mass of the drug molecules. Thus, the developed IBPD may be suitable for use as a localized intravaginal drug delivery system for the potential treatment and prevention of HIV infection and STIs.
